WACKER and Amyris partner on bio-based personal-care ingredients

Key highlights
  • WACKER and Amyris will jointly develop and evaluate bio-based functional ingredients and building blocks for personal-care applications.
  • WACKER plans to extend its silicone portfolio with bio-based raw materials and test formulation and application compatibility at customer sites.
  • WACKER currently ferments cyclodextrin and cysteine while Amyris supplies precision-fermentation-derived molecules.
  • Amyris operates fermentation plants in Barra Bonita and Campinas, Brazil, and a cosmetic finishing plant in Leland, North Carolina.

Scope of collaboration

WACKER and Amyris will jointly develop and evaluate bio-based functional ingredients and molecular building blocks for cosmetics and personal-care applications, focusing on novel functional compounds and new formulation approaches announced at the in-cosmetics trade show in Paris.

Technical focus

The collaboration emphasizes assessing the functional potential of bio-based molecules in formulations, expanding WACKER’s silicone portfolio to include renewable raw materials, and verifying formulation and application compatibility at customer sites.

Capabilities contributed

Amyris supplies precision-fermentation–derived molecules produced using engineered microorganisms and operates fermentation and finishing facilities; WACKER contributes silicone chemistry, formulation know-how, and experience in fermentative production of cyclodextrin and cysteine for personal care.

Production and integration

Both companies will evaluate the scalability and integration of selected Amyris-produced raw materials into existing production structures, using WACKER’s development and testing capabilities to advance market-ready solutions.

Source: WACKER

chemXplore Weekly

The week’s project milestones and project news from the chemical industry, free every Wednesday.

Free. One email a week. Unsubscribe any time.

Related articles

30 July 2026
WACKER Q2 2026 results — PACE savings and pension effect boost earnings

Q2 sales €1.52bn; EBITDA €211m aided by cost cuts and a €36.7m pension revaluation; net income includes €243m from Siltronic sale; full‑year guidance adjusted.

13 August 2026
WACKER expands into EU pet‑food additives with fermented L‑cysteine and L‑cystine

EU approval allows plant‑based, fermented L‑cysteine/L‑cystine as sensory additives for all animal species; products suit multiple dosage forms and are supplied from Europe.